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COMMENTARY
Annotating DNA Variants Is the Next Major
Goal for Human Genetics
Garry R. Cutting1,*
Clinical genetic testing has undergone a dramatic transformation in the past two decades. Diagnostic laboratories that previously tested
for well-established disease-causing DNA variants in a handful of genes have evolved into sequencing factories identifying thousands of
variants of known and unknown medical consequence. Sorting out what does and does not cause disease in our genomes is the next
great challenge in making genetics a central feature of healthcare. I propose that closing the gap in our ability to interpret variation
responsible for Mendelian disorders provides a grand and unprecedented opportunity for geneticists. Human geneticists are well placed
to coordinate a systematic evaluation of variants in collaboration with basic scientists and clinicians. Sharing of knowledge, data,
methods, and tools will aid both researchers and healthcare workers in achieving their common goal of defining the pathogenic poten-
tial of variants. Generation of variant annotations will inform genetic testing and will deepen our understanding of gene and protein
function, thereby aiding the search for molecular targeted therapies.Hunting for DNA variants responsible
for Mendelian conditions has been
a spectacularly successful endeavor
in human genetics over the past
30 years. Almost 4,000 Mendelian
phenotypes now have disease-asso-
ciated genes identified (OMIM), and
this number will continue to grow as
genome-wide sequencing is applied
to disorders segregating in a Mende-
lian fashion in one or a few fam-
ilies.1 However, our ability to interpret
the disease implications of individual
variants has not kept pace with the
ease with which we find them.2–4 To
describe a stable transmissible change
in DNA, the term ‘‘variant’’ is pre-
ferred over the term ‘‘mutation’’ in
this commentary for reasons outlined
in Box 1. Assigning pathogenicity is
relatively straightforward when one
variant (or a few variants) account
for all (or almost all) cases (e.g., sickle
cell anemia [MIM 603903] or achon-
droplasia [MIM 100800]).9–11 Unfor-
tunately, allelic heterogeneity is the
rule for most Mendelian disorders
(Figure 1). As might be expected, our
understanding of the phenotypic con-
sequences of these variants correlates
to some degree with their frequency
in affected individuals. Disease signif-
icance is generally known for variants
that account for a substantial fraction
of disease-causing alleles but is incom-
plete or unknown for less frequent1McKusick-Nathans Institute of Genetic Medicine an
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by allelic heterogeneity is even greater
in disorders where deleterious vari-
ants in a small number of genes
combine to create a disease pheno-
type (i.e., oligogenic disorders) and
in cancer caused by de novo variants
in somatic tissue. These conditions
present complexities that are beyond
the scope of this commentary but
have been addressed by others.12–14
Although many variants have been
associated with common conditions,
I propose that we tackle penetrant
variants underlying Mendelian disor-
ders first.15 Assigning disease liability
to variants associated with individu-
ally rare ‘‘single-gene’’ disorders that
in aggregate are estimated to affect
25–30 million individuals in the US
will be of high medical impact.
Provision of an accurate assessment
of disease liability of variants is essen-
tial for clinical applications such as
diagnosis, newborn screening, carrier
screening, selection for mutation-
specific therapy, and association be-
tween genes and rare familial diseases.
The introduction of DNA sequencing
to clinical molecular genetic labora-
tories almost two decades ago enabled
the detection of variants irrespective
of their frequency or annotation
status. DNA diagnostic laboratories
endeavored to interpret variants by
using guidelines from expert com-d Department of Pediatrics, Johns Hopkins Universi
4 by The American Society of Human Genetics. All
The American Journal of Humittees, publications, and mutation
databases, and many became highly
competent in the interpretation of
the limited set of genes in their test
menu. Despite these efforts, clinical
testing laboratories have recognized
for some time that a substantial
number of variants of unknown sig-
nificance remain.8,16 Wide deploy-
ment of next-generation exome
and whole-genome sequencing in
the clinical arena and reduction
in the cost of sequencing will increase
the number of variants identified
in clinical settings.17 Many of these
variants will be rare, and it is likely
that the disease implications of only
a fraction will be determined if
current trends continue.4 Indeed, it
is likely that the gap between what
we can and cannot interpret will
continue to increase in the foreseeable
future (Figure 2).
Numerous efforts to address the
‘‘interpretive gap’’ have been under-
way. Locus-specific databases (LSDBs)
have been created to catalog the
variants found in a gene or a set of
genes. Sharing of these data in a
website or within aggregative deposi-
tories such as the Leiden Open
Variation Database (LOVD),18 the
Human Gene Mutation Database,19
Gen2Phen,20 ClinVar,21 and others
provides an important service to the
clinical and research communities.ty School of Medicine, Baltimore, MD 21205, USA
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Box 1. What’s in a Name: Mutation versus Variant
‘‘Mutation’’ is defined bymost dictionaries as the process that introduces a heritable change into the structure of a
gene.5 The term does not infer a deleterious effect; however, the use of ‘‘mutation’’ in association with radiation
damage andwithdisease states has linked anegative connotation to theword.6 Theproblemof inferringdeleterious
consequences when using the term ‘‘mutation’’ is that some changes in DNA are advantageous from an
evolutionary point of view. On the other hand, ‘‘variant’’ is usually defined in terms of an organism that differs
in some way from an accepted standard.5 Variant can also be used for phenotypic differences that are not
genetic.5 The application of the term ‘‘variant’’ to changes in DNA structure was popularized by genome-wide
association studies of common disorders. ‘‘Variant’’ as opposed to ‘‘mutation’’ is preferred because most of the
DNA alterations that contribute risk to complex genetic conditions are of unknown effect and are frequent in
the population. These features contrast withMendelian-disorder DNA changes, which usually occur within known
functional regions of our genomes, are highly penetrant for disease states, and are generally rare in that few alleles
exceed 1% inanypopulation. Thus, ‘‘mutation’’ continues to beusedwidely inpublications reporting thediscovery
of DNA changes that cause rare disease inherited in a Mendelian fashion.7 Experts who have tackled the terminol-
ogy conundrum prefer the term ‘‘variant’’ so as to avoid the negative connotations that have accrued from the lay
perspective. Annotation such as ‘‘disease-causing variant’’ or ‘‘pathogenic variant’’ is recommended when the
phenotypic consequence of a variant has been established.8 Considering that our goal as geneticists is to annotate
variation in our genome according to disease risk, the use of an unburdened term will facilitate understanding in
medical and public health settings, especially when we need to convey the concept that some DNA variants cause
disease but that others do not. The proposed approach does not exclude continued use of ‘‘mutation,’’ but it does
advocate careful consideration of the context in which the term is used.Implementation of universal stan-
dards22,23 will enable confederation
of LSDBs that should coalesce into
federated arrangements.24 To this
end, the National Institutes of Health
have recently announced funding
of three clinical variant resource
projects that will lead to the forma-
tion of a federated ‘‘Clinical GenomeFigure 1. Allelic Heterogeneity as Represen
Variants Reported per Gene in the LOVD
Variants from the Leiden Open Variation Dat
with properly configured reference sequence
unique alleles reported per gene. If a gene w
instances), the raw data were parsed such t
given gene was reported. Variants per gene
there were <500 and multiples of 50 when
F.A.C. Fokkema and Johan T. den Dunnen (pe
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of these projects will support the
activities of the International Collabo-
ration for Clinical Genomics, a collab-
orative organization that evolved
from the highly successful interna-
tional project to annotate copy-
number variants.25 Efforts to promote
sharing of variant data at the world-ted by the Distribution of the Number of
abase (LOVD) version 2.0–24 or higher and
s were used for extracting the number of
as present in multiple databases (duplicate
hat the highest number of variants per a
were binned into multiples of ten when
there were R500. Data are courtesy of Ivo
rsonal communication).
4, 5–10, January 2, 2014wide level have been led by the
Human Variome Project,26,27 and
recently the Global Alliance has pro-
posed standards for data exchange.28
Understanding the disease liability
of variants is an immense undertaking
both at the level of ‘‘big data’’ and at
the level of individual detail. Existing
repositories such as the LOVD, which
has over 2.2 million unique variants
dispersed among approximately
170,000 individuals, illustrate the
scale of the challenge we face. Reposi-
tories containing hundreds of thou-
sands of individuals, each of whom
has thousands of potentially clinically
relevant DNAvariants, is undoubtedly
a big-data issue.29 Furthermore,
accruing information on the qualita-
tive and quantitative variables neces-
sary for unambiguously describing
a human phenotype presents an
informatics challenge that exceeds
the analytic and storage demands
of DNA variants. Substantial server
capacity and data storage already exist
in the commercial sector, so the hard-
ware and data handling know-how
is within reach for building the infra-
structure to contain and mani-
pulate the sequence and associated
Figure 2. An Illustration of the Growing Gap in Our Understand-
ing of the Clinical Implications of DNA Variants over Time
As the cost of sequencing declines, the total number of variants
identified is expected to grow dramatically (MassGenomics).
Annotated variants represent only a fraction of the total number
of variants identified.2,15 Over time, the proportion of annotated
variants is not expected to increase at the same rate as the discov-
ery of rare variants, causing an ever increasing ‘‘interpretive gap.’’phenotype information.
However, annotation of
the clinical and functional
consequences of DNA vari-
ants will require gene- and
phenotype-centered exper-
tise.14,25,30 Moreover, the
assembly of phenotype in-
formation will be greatly
facilitated by the participa-
tion of the medical profes-
sionals caring for the indi-
viduals involved.31 One
important risk of data
collection from individuals
who have sought medical
expertise is ascertainment
bias, which could lead toincorrect estimates of penetrance.14
Autosomal-dominant disorders that
frequently manifest incomplete pene-
trance and variable expressivity might
be particularly prone to this problem.
Public repositories of variant data
derived from verified phenotypically
‘‘normal’’ individuals would be most
useful in assessing penetrance.32
Although the 1000 Genomes Project
has been used for estimating pene-
trance,33 the absence of phenotypic
data limits the clinical usefulness of
this project. Distilling high-quality
clinical data person by person exem-
plifies the individual detail that will
be needed for generating reliable
correlations between genotype and
phenotype.34–36
Current DNA-variant repositories
are primarily driven by genotype in-
formation.24,37 Although these are
useful for cataloging the reported
variants in disease-associated genes,
annotation of variants according to
disease liability might be inaccurate
for a not insignificant fraction of
entries.3,4 In some cases, these inac-
curacies can be traced to incomplete
characterization of a disease allele
where the identified variant is benign
and the pathologic variant is an
undetected or unrecognized variant
in cis.14 Other causes of error can be
due to submissions that are bereft
of clinical information sufficiently
detailed for ascertaining disease sta-
tus.37 To date, much of the submitted
data are from research laboratoriesthat might not have direct access to
affected individuals. Clinical genetic-
testing laboratories are a growing
source of variant data, but many labo-
ratories receive incomplete pheno-
type information.25,38 Collection of
additional clinical information from
referrers is feasible but generally not
compatible with the fiscal challenges
of a highly competitive field. Even
so, the increase in genomic knowl-
edge derived from the posting of
data to centralized repositories is
likely to benefit clinical laboratories
in ways that outweigh the financial
cost of submission. Publications pro-
vide an important source of informa-
tion needed for variant annotation.
Aggregative resources such as OMIM
and GeneReviews provide critiqued
compilations of published pheno-
type-associated variants. However,
only a minor fraction of variants
are studied to the degree that merits
publication.15 Furthermore, unre-
solved discrepancies are often found
in published work.3 Given these limi-
tations, continued accrual of variant
data in the same modes as employed
to date appears unlikely to provide
sufficient clinical and functional
information necessary for accurate
assessment of penetrance for the
huge number of nonannotated DNA
variants.14
The clinical challenges created by
incomplete annotation of variants are
illustrated by the gene responsible for
cystic fibrosis (CF [MIM 219700]).The American Journal of Human GeneThe CF Mutation Data-
base was created shortly
after the identification of
CF transmembrane conduc-
tance regulator (CFTR [MIM
602421]), in which over
1,900 variants have been re-
ported. The disease liability
of the most common muta-
tion, c.1521_1523delCTT
(p.Phe508del), and 22 other
mutations included in the
American College of Medical
Genetics testing panel has
been established for over a
decade.39 The original panel
had to be revised as a result
of an unrecognized complexallele and a mutation that had lower-
than-estimated prevalence.40 Other-
wise, the disease assignments of the
remaining 22 mutations have stood
the test of time.41 However, the 85%
sensitivity of the mutation panel for
CF-causing alleles in whites (the sensi-
tivity is lower in Hispanic and
nonwhite groups42) was unsatisfac-
tory for a number of reasons. First,
newborn screening for CF became uni-
versal in the US by 2010, and genetic
testing was adopted as a second tier
of the screen in 48 states.43 A sensi-
tivity of 85% left almost 30% of
newborns with insufficient genetic
evidence to confirm a diagnosis of
CF.42 Second, white couples who un-
derwent CF carrier screening in which
one partner tested positive and the
other partner tested negative were left
with a residual risk of having a child
with CF (~1:1,000) that was higher
than if no testing had been performed
(~1:3,200). Discovery of variants of
unknown clinical significance after
sequencing of CFTR in newborns
and members of pregnant couples
compounded the diagnostic chal-
lenge.44 Third and finally, the break-
through in mutation-specific therapy
brought a new urgency to annotating
CFTR variants with the goal of
designing treatments for all individ-
uals with CF.45,46
For assigning disease penetrance to
less common and rare variants of
CFTR, a new approach was taken for
avoiding the limitations inherenttics 94, 5–10, January 2, 2014 7
in collating data from laboratories
or published sources. Given that
genetic-testing results are returned to
the referring source, it appeared
reasonable to collect phenotype and
genotype information directly from
clinics and patient registries. Because
the veracity of the phenotype data
associated with each genotype is crit-
ical scientific knowledge, it was essen-
tial to provide a system by which
these data could be traced to original
sources. This was achieved by a pro-
cess called microattribution, in which
the data contributors provide a
researcher ID, allowing unambiguous
crediting and validation of the infor-
mation source.47,48 The process was
widely accepted and appreciated by
clinical colleagues who were collating
phenotype data pertaining to the
variants carried by the individuals
for whom they cared. Using this
approach, the Clinical and Functional
Translation of CFTR (CFTR2) Project
accrued genotype and phenotype
data on almost 40,000 CF-affected in-
dividuals from clinics in North Amer-
ica and Europe.32 The second produc-
tive approach was engagement of
basic science colleagues in academic
and industrial settings for analyzing
the functional consequences of vari-
ants that cause amino acid substitu-
tions and changes in splice sites.
This step was essential because
missense variants have been
the most difficult type of variant for
which to reliably predict effect on
the function of the encoded gene
product.8 Although our understand-
ing of the functional thresholds that
transition between diseases and
healthy states is incomplete for CF,
as it is for many disorders, unambigu-
ous assignment was possible for a sub-
stantial fraction of missense variants
that caused complete or near com-
plete loss of function. At the very
least, functional assays provide an in-
dependent assessment of the delete-
rious potential of variants.
Clinical and functional evidence
of pathogenicity was combined for
assigning disease liability to 127 vari-
ants that occurred at a frequency of
0.01% or higher in the CFTR2 data-8 The American Journal of Human Genetics 9base (95.4% of total alleles). Results
of the study will have immediate
clinical application in screening and
diagnostic settings. However, it is
important to note that determination
of the clinical and functional effects
of rare CFTR variants is useful well
beyond the improvement in test
sensitivity. The involvement of basic
scientists facilitated ‘‘reverse trans-
lation’’ of the functional effects of
deleterious variants upon protein
folding and response to therapeutic
compounds. The naturally occurring
missense variants provide valuable
insight into the protein biogenesis
and function; such insight is not
easily obtained from systematic
empiric mutagenesis.49 The identifi-
cation of regions involved in domain
interaction can inform the search for
small compounds that can stabilize
aberrant proteins produced in affected
individuals.50 These insights are
essential in disorders such as CF,
where destabilizing variants account
for a large fraction of the disease-
causing alleles.51 Moreover, the
characterization of the molecular con-
sequences facilitates binning of
disease-associated variants into dys-
functional groups that might respond
to available therapeutic compounds.
For example, Ivacaftor (Kalydeco)
is efficacious for CF-affected individ-
uals carrying the missense variant
c.1652G>A (p.Gly551Asp).45,52 At
least a dozen rare variants alter CFTR
function in a manner similar to that
of p.Gly551Asp, and seven of these
have already been shown to respond
to Ivacaftor.53 Broadening the applica-
bility of molecular therapies for rare
diseases is highly desirable given their
high cost of development. Finally,
increasing the number of variants
with established clinical and func-
tional effects enables more detailed
analysis of the correlation between
genotype and phenotype.
A key factor in the success of the
CFTR2projectwas cooperation among
geneticists, clinicians, basic scientists,
and their staff.Most of theparticipants
contributed their data and efforts
without remuneration because each
recognized that a comprehensive4, 5–10, January 2, 2014approach to variant annotationwould
benefit those affected by CF. CFTR2
followed templates created by prior
successful cross-disciplinary efforts
that addressed allelic heterogeneity
in phenylketonuria (MIM 261600)54
and hemoglobinopathies (MIM
141900).47 Disorders manifesting
dominant or X-linked patterns of
Mendelian inheritance have also
been tackled by team efforts and
approaches outlined for recessive con-
ditions.55 In some cases, investigators
capitalized on mechanisms that are
highly informative for variant annota-
tion (e.g., de novo changes, gain-of-
function substitutions in discrete
domains, and expansion of repeats).
Similarly, researchers, clinicians, and
bioinformaticists have formed inter-
national working groups to assess the
pathogenicity of variants predisposing
to familial forms of cancer. Successful
projects focused on cancers of the
breast (Evidence-based Network for
the InterpretationofGermlineMutant
Alleles) and gastrointestinal tract
(International Society for Gastrointes-
tinal Hereditary Tumors) illustrate
the generalizability of collaborative
approaches.56,57
In summary, the identification of
deleterious variants responsible for a
rare Mendelian disorder generally
provides the first insight into its
molecular basis. Allelic heterogeneity
presents a challenge to genetic diag-
nosis but also an opportunity to
capitalize on naturally occurring vari-
ation as dissection planes for under-
standing the function of the encoded
product, molecular pathogenesis,
and therapy development. Geneticists
are uniquely placed to coordinate the
investigation of variants by fostering
collaboration with scientists focused
on gene function and clinicians car-
ing for individuals carrying disease-
causing alleles. Most Mendelian
diseases are quite rare in comparison
to the aforementioned conditions.
However, the methods employed,
such as data gathering from clinics
and patient registries and colla-
borative functional assessment, are
applicable for many conditions,
regardless of prevalence. Integration
of multidisciplinary efforts to rigor-
ously annotate variants can have im-
mediate medical application and can
set the stage for therapy development.
Finally, sharing of results with central
repositories will reduce the interpre-
tive gap and, in doing so, will increase
the clinical utility of genetic testing.Acknowledgments
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